NVCR NovoCure Ltd

Price (delayed)

$11.3

Market cap

$1.32B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.06

Enterprise value

$1.45B

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 37
Highlights
NovoCure's debt has plunged by 71% YoY
NVCR's EPS is up by 34% year-on-year and by 18% since the previous quarter
The company's quick ratio has surged by 56% YoY but it fell by 13% QoQ

Key stats

What are the main financial stats of NVCR

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-4.48%
1 week
-9.82%
1 month
-19.69%
1 year
-0.18%
YTD
-12.61%
QTD
-29.15%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$725.39M
Gross profit
$558.67M
Operating income
-$124.55M
Net income
-$121.73M
Gross margin
77%
Net margin
-16.8%
NovoCure's net margin has increased by 39% YoY and by 21% from the previous quarter
NovoCure's operating margin has increased by 37% YoY and by 22% QoQ
The net income has grown by 31% YoY and by 18% from the previous quarter
NovoCure's operating income has increased by 30% YoY and by 19% QoQ

Price vs fundamentals

How does NVCR's price correlate with its fundamentals

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
P/E
N/A
P/B
3.75
P/S
1.82
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.99
NVCR's EPS is up by 34% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 59% lower than the 5-year quarterly average of 9.1 and 18% lower than the last 4 quarters average of 4.6
The equity has increased by 3.7% since the previous quarter and by 2.7% year-on-year
NVCR's price to sales (P/S) is 72% lower than its 5-year quarterly average of 6.6 and 21% lower than its last 4 quarters average of 2.3
The company's revenue rose by 13% YoY and by 3.7% QoQ

Efficiency

How efficient is NovoCure business performance
NVCR's return on sales is up by 37% year-on-year and by 22% since the previous quarter
NovoCure's return on equity has increased by 29% YoY and by 19% QoQ
The company's return on assets fell by 9% YoY but it rose by 5% QoQ
NovoCure's ROIC has increased by 9% from the previous quarter but it has decreased by 4.1% YoY

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 73% more than its total liabilities
The company's current ratio has surged by 61% YoY but it fell by 14% QoQ
The company's quick ratio has surged by 56% YoY but it fell by 13% QoQ
NovoCure's debt is 34% less than its equity
NVCR's debt to equity has shrunk by 72% YoY and by 4.3% QoQ
NovoCure's debt has plunged by 71% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.